Compare Fidelity National Information Servcs Inc (FIS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Mesoblast Limited — how do they compare? Fidelity National Information Servcs Inc trades at $42.6 (market cap $22.05B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Fidelity National Information Servcs Inc is far larger — about 10× Mesoblast Limited's market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| FIS | MESO | |
|---|---|---|
Market Cap | $22.05B | $2.21B |
Sector | Technology | Technology |
52-Week High | $72.77 | $20.96 |
52-Week Low | $37.72 | $12.88 |
Enterprise Value | $42.56B | $2.21B |
Dividend Yield | 4.12% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
